Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) DAP Kinase 1 Antibodies:
anti-Rat (Rattus) DAP Kinase 1 Antibodies:
anti-Human DAP Kinase 1 Antibodies:
Go to our pre-filtered search.
Human Monoclonal DAP Kinase 1 Primary Antibody for IF, IP - ABIN967885
Cohen, Feinstein, Kimchi: DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. in The EMBO journal 1997
Show all 2 Pubmed References
Human Monoclonal DAP Kinase 1 Primary Antibody for IF, IP - ABIN967884
Deiss, Feinstein, Berissi, Cohen, Kimchi: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. in Genes & development 1995
Show all 2 Pubmed References
Human Monoclonal DAP Kinase 1 Primary Antibody for IP, MA - ABIN265776
Hearnden, Powers, Elmogassabi, Lowe, Murdoch: Methyl-donor depletion of head and neck cancer cells in vitro establishes a less aggressive tumour cell phenotype. in European journal of nutrition 2017
Human Polyclonal DAP Kinase 1 Primary Antibody for IF (p), IHC (p) - ABIN732983
Liu, Ao, Zhou, Cui, Zhou, Yuan, Xiang, Cao, Liu: CpG island hypermethylation of multiple tumor suppressor genes associated with loss of their protein expression during rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine. in Biochemical and biophysical research communications 2010
Inhibition of DAPK1 by deleting a catalytic domain or a death domain of DAPK1 rescues the Excitatory pyramidal neurons in the entorhinal cortical layer II region synaptic loss
in Alzheimer's disease (AD) brains, elevated DAPK1 levels showed co-relation with the increase of APP (show APP Antibodies) phosphorylation. Combined together, these results suggest that DAPK1 promotes the phosphorylation and amyloidogenic processing of APP (show APP Antibodies), and that may serve a potential therapeutic target for AD.
This study demonstrate that phosphorylation of Tau at Serine 262 by the kinase domain of DAPK1 mediates spine damage and the subsequent neuronal death in ischemic stroke.
DAPK1-p53 (show TP53 Antibodies) interaction is a preferred target for therapeutic intervention of stroke.
Suggest that DAPK1 is a novel regulator of tau protein abundance, and that DAPK1 upregulation might contribute to tau-related pathologies in Alzheimer disease.
the DAPK1-p53 (show TP53 Antibodies) interaction is a signaling point of convergence of necrotic and apoptotic pathways
a new function of DAPK in suppressing TNF (show TNF Antibodies)-induced STAT3 (show STAT3 Antibodies) activation, was identified.
TSC2 (show TSC2 Antibodies) binds to the death domain of DAPK. This interaction is required for TSC2 (show TSC2 Antibodies) to reduce DAPK protein levels and half-life. DAPK is regulated by the lysosome pathway. Lysosome inhibition blocks TSC2 (show TSC2 Antibodies)-mediated degradation of DAPK.
Results identify DAPK as a molecule required for full production of IL-1beta (show IL1B Antibodies) and functional assembly of the NLRP3 (show NLRP3 Antibodies) inflammasome.
Study reports that cerebral ischemia recruits death-associated protein kinase 1 (DAPK1) into the NMDA receptor NR2B (show GRIN2B Antibodies) protein complex in the cortex of adult mice.
The current study supports a relevant role for p15 (show CDKN2B Antibodies), p16 (show CDKN2A Antibodies), and DAPK hypermethylation in the genesis of the plasma cell neoplasm. DAPK hypermethylation also might be an important step in the progression from MGUS to MM.
DAPK1 methylation is associated with the risk of gastrointestinal cancer.
downregulation of HOXC9 (show HOXC9 Antibodies) releases its transcriptional inhibition of DAPK1, resulting in the activation of the DAPK1-Beclin1 (show BECN1 Antibodies) pathway, which induces autophagy in glioblastoma cells
findings evidence a positive correlation between SIRT1 (show SIRT1 Antibodies) and BCL6 (show BCL6 Antibodies) expression increase in follicular lymphomas (FL) . SIRT1 (show SIRT1 Antibodies) methylation decreases in FL and diffuse large-B cell lymphomas (DLBCL)and this parallels the increase of KLF4 (show KLF4 Antibodies), DAPK1 and SPG20 (show SPG20 Antibodies) methylation
results suggest that DAPK1 is an important prognostic marker and therapeutic target for bladder cancer and have identified possible therapeutic agents for future testing in bladder cancer models with low DAPK1 expression
Study provides evidence that DAPK1 is a negative-feedback regulator of the RIG-I (show DDX58 Antibodies) pathway. RIG-I (show DDX58 Antibodies)-mediated antiviral signaling activates DAPK1 kinase activity and DAPK1 inactivates RIG-I (show DDX58 Antibodies) RNA sensing by direct phosphorylation of RIG-I (show DDX58 Antibodies).
Meta-analysis suggested that aberrant methylation of DAPK promoter was associated with head and neck squamous cell carcinoma.
our study characterized DAPK1 as a novel transcriptional target of BRMS1 (show BRMS1 Antibodies). Transcriptional activation of DAPK1 might be another important mechanism accounting for the metastasis suppressive activity of BRMS1 (show BRMS1 Antibodies).
The result suggests that DAPK promoter methylation is significantly increased in bladder cancer patients compared to normal controls. DAPK promoter methylation could serve as a biomarker for bladder cancer detection and management.
Death-associated protein kinase 1 is a positive mediator of gamma-interferon induced programmed cell death. DAPK1 encodes a structurally unique 160-kD calmodulin dependent serine-threonine kinase that carries 8 ankyrin repeats and 2 putative P-loop consensus sites. It is a tumor suppressor candidate.
death-associated protein kinase 1
, death-associated protein kinase 1-like
, DAP kinase 1